Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 01/20 10:01:02 pm
62.53 USD   +3.65%
01/20 MERCK : Announces Settlement and License Agreement Resolving KEYTRUD..
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/20 DOW MOVERS : Ge, mrk
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2012 | 12:03am CET
   By Peter Loftus 
   Of  
 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable.

Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable.

Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said.

A Mylan spokeswoman couldn't immediately be reached.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
01/20 MERCK : Announces Settlement and License Agreement Resolving KEYTRUDA® (pembroli..
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/20 DOW MOVERS : Ge, mrk
01/19 STUDIES FROM MERCK & COMPANY PROVIDE : PCSK9 as an...
01/19 MERCK : Reports Outline Pharmacology and Toxicology Study Findings from Merck & ..
01/19 MERCK : Researchers at Merck & Company Discuss Findings in Bioanalysis (Reductio..
01/19 INCYTE : and Merck to Advance Clinical Development Program Investigating the Com..
01/19 MERCK : Recent Findings from Merck & Company Advance Knowledge in Bioanalysis (A..
01/19 MERCK : to Participate at the 35th Annual J.P. Morgan Healthcare Conference
01/19 RESEARCHERS AT MERCK & COMPANY TARGE : A Powerful...
More news
Sector news : Pharmaceuticals - NEC
01/20 European shares ease ahead of Trump inauguration
01/20 Bristol-Myers shares fall on lung cancer timeline setback
01/19DJRival to EpiPen Allergy Treatment to Return to Market--Update
01/19DJRival to EpiPen Allergy Treatment to Return to Market
01/19 Davos CEOs 'go local' on supply chain in Trump era
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
01/20 SNIPPET ROUNDUP : Opdivo's First-Line Lung Combo Delay And Colucid's Lilly Windf..
01/20 ASCO-GI : Opdivo Heads Close Pack Of Anti-PD-1s In Gastric Cancer
01/20 Merck settles Keytruda patent fight with Bristol-Myers and Ono Pharma, agrees..
01/20 Implications Of The Latest Smash In Bristol-Myers Squibb Stock
01/20 Why Gilead Is Undervalued
Advertisement
Financials ($)
Sales 2016 39 931 M
EBIT 2016 13 699 M
Net income 2016 5 950 M
Debt 2016 3 981 M
Yield 2016 2,97%
P/E ratio 2016 30,17
P/E ratio 2017 17,86
EV / Sales 2016 4,42x
EV / Sales 2017 4,37x
Capitalization 172 404 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 68,2 $
Spread / Average Target 9,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.6.22%172 404
JOHNSON & JOHNSON-0.92%310 549
ROCHE HOLDING LTD.1.29%200 499
PFIZER INC.-2.19%192 792
NOVARTIS AG-4.32%185 152
SANOFI-1.66%104 532
More Results